根治性前列腺切除术后的生化复发——一项大型、全面、基于人群的长期随访研究。

IF 1.4 4区 医学 Q3 UROLOGY & NEPHROLOGY
Scandinavian Journal of Urology Pub Date : 2022-08-01 Epub Date: 2022-08-21 DOI:10.1080/21681805.2022.2108140
Elin Axén, Johan Stranne, Marianne Månsson, Erik Holmberg, Rebecka Arnsrud Godtman
{"title":"根治性前列腺切除术后的生化复发——一项大型、全面、基于人群的长期随访研究。","authors":"Elin Axén,&nbsp;Johan Stranne,&nbsp;Marianne Månsson,&nbsp;Erik Holmberg,&nbsp;Rebecka Arnsrud Godtman","doi":"10.1080/21681805.2022.2108140","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>We evaluated long-term risk for biochemical recurrence and subsequent prognosis in a population-based cohort.</p><p><strong>Material and methods: </strong>We used register-based data to evaluate 6 675 consecutive patients having radical prostatectomy in Västra Götaland county in Sweden during 1995-2014. Patients were followed until death or end of study, 31 December 2014. Data were collected from registers on national, regional and local level and linked by means of the Swedish personal identity number. Biochemical recurrence was defined as PSA ≥0.2 ng/ml; failure as hormonal treatment, metastasis or prostate cancer death. Survival analysis was used to estimate time to biochemical recurrence and time to failure after biochemical recurrence for patients with 0 - 2 years, 2-5 years, 5-10 years and >10 years interval to biochemical recurrence, respectively.</p><p><strong>Results: </strong>A total of 1214 men had biochemical recurrence during follow-up. Biochemical recurrence-free survival was 83% (95% confidence interval [CI] 82-84%), 75% (95% CI 74-77%) and 69% (95% CI 67-71%) at 5, 10 and 15 years, respectively. Cumulative incidence of failure for all patients 15 years after biochemical recurrence was 50% (95% CI 43-55%) in competing risk analysis. The risk of failure after biochemical recurrence was highest among patients having biochemical recurrence within 2 years from surgery. Incomplete data on PSA-history is a limitation.</p><p><strong>Conclusions: </strong>The risk for biochemical recurrence persists 15 years after surgery. Follow-up should continue as long as treatment would be considered in case of recurrent disease.</p>","PeriodicalId":21542,"journal":{"name":"Scandinavian Journal of Urology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Biochemical recurrence after radical prostatectomy - a large, comprehensive, population-based study with long follow-up.\",\"authors\":\"Elin Axén,&nbsp;Johan Stranne,&nbsp;Marianne Månsson,&nbsp;Erik Holmberg,&nbsp;Rebecka Arnsrud Godtman\",\"doi\":\"10.1080/21681805.2022.2108140\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>We evaluated long-term risk for biochemical recurrence and subsequent prognosis in a population-based cohort.</p><p><strong>Material and methods: </strong>We used register-based data to evaluate 6 675 consecutive patients having radical prostatectomy in Västra Götaland county in Sweden during 1995-2014. Patients were followed until death or end of study, 31 December 2014. Data were collected from registers on national, regional and local level and linked by means of the Swedish personal identity number. Biochemical recurrence was defined as PSA ≥0.2 ng/ml; failure as hormonal treatment, metastasis or prostate cancer death. Survival analysis was used to estimate time to biochemical recurrence and time to failure after biochemical recurrence for patients with 0 - 2 years, 2-5 years, 5-10 years and >10 years interval to biochemical recurrence, respectively.</p><p><strong>Results: </strong>A total of 1214 men had biochemical recurrence during follow-up. Biochemical recurrence-free survival was 83% (95% confidence interval [CI] 82-84%), 75% (95% CI 74-77%) and 69% (95% CI 67-71%) at 5, 10 and 15 years, respectively. Cumulative incidence of failure for all patients 15 years after biochemical recurrence was 50% (95% CI 43-55%) in competing risk analysis. The risk of failure after biochemical recurrence was highest among patients having biochemical recurrence within 2 years from surgery. Incomplete data on PSA-history is a limitation.</p><p><strong>Conclusions: </strong>The risk for biochemical recurrence persists 15 years after surgery. Follow-up should continue as long as treatment would be considered in case of recurrent disease.</p>\",\"PeriodicalId\":21542,\"journal\":{\"name\":\"Scandinavian Journal of Urology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":1.4000,\"publicationDate\":\"2022-08-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Scandinavian Journal of Urology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/21681805.2022.2108140\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2022/8/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scandinavian Journal of Urology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/21681805.2022.2108140","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/21 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:我们在以人群为基础的队列中评估生化复发的长期风险和随后的预后。材料和方法:我们使用基于登记的数据评估1995-2014年期间瑞典Västra Götaland县连续6 675例根治性前列腺切除术患者。随访患者至2014年12月31日死亡或研究结束。数据是从国家、区域和地方各级的登记册中收集的,并通过瑞典个人身份号码进行联系。生化复发定义为PSA≥0.2 ng/ml;如激素治疗失败、前列腺癌转移或死亡。采用生存分析分别估计生化复发间隔0 ~ 2年、2 ~ 5年、5 ~ 10年和>10年患者生化复发至生化复发时间和生化复发失败时间。结果:随访期间生化复发1214例。5年、10年和15年的生化无复发生存率分别为83%(95%可信区间[CI] 82-84%)、75% (95% CI 74-77%)和69% (95% CI 67-71%)。在竞争风险分析中,所有患者在生化复发后15年的累积失败率为50% (95% CI 43-55%)。术后2年内生化复发的患者生化复发失败的风险最高。不完整的psa病史数据是一个限制。结论:术后15年生化复发风险持续存在。如果疾病复发,只要考虑治疗,就应继续随访。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Biochemical recurrence after radical prostatectomy - a large, comprehensive, population-based study with long follow-up.

Objective: We evaluated long-term risk for biochemical recurrence and subsequent prognosis in a population-based cohort.

Material and methods: We used register-based data to evaluate 6 675 consecutive patients having radical prostatectomy in Västra Götaland county in Sweden during 1995-2014. Patients were followed until death or end of study, 31 December 2014. Data were collected from registers on national, regional and local level and linked by means of the Swedish personal identity number. Biochemical recurrence was defined as PSA ≥0.2 ng/ml; failure as hormonal treatment, metastasis or prostate cancer death. Survival analysis was used to estimate time to biochemical recurrence and time to failure after biochemical recurrence for patients with 0 - 2 years, 2-5 years, 5-10 years and >10 years interval to biochemical recurrence, respectively.

Results: A total of 1214 men had biochemical recurrence during follow-up. Biochemical recurrence-free survival was 83% (95% confidence interval [CI] 82-84%), 75% (95% CI 74-77%) and 69% (95% CI 67-71%) at 5, 10 and 15 years, respectively. Cumulative incidence of failure for all patients 15 years after biochemical recurrence was 50% (95% CI 43-55%) in competing risk analysis. The risk of failure after biochemical recurrence was highest among patients having biochemical recurrence within 2 years from surgery. Incomplete data on PSA-history is a limitation.

Conclusions: The risk for biochemical recurrence persists 15 years after surgery. Follow-up should continue as long as treatment would be considered in case of recurrent disease.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Scandinavian Journal of Urology
Scandinavian Journal of Urology UROLOGY & NEPHROLOGY-
CiteScore
2.90
自引率
6.70%
发文量
70
期刊介绍: Scandinavian Journal of Urology is a journal for the clinical urologist and publishes papers within all fields in clinical urology. Experimental papers related to clinical questions are also invited.Important reports with great news value are published promptly.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信